#GU15 - ASCENDE-RT: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer - Session Highlights

ORLANDO, FL, USA (UroToday.com) - In this session, Dr. Scott Tyldesley presented data from the Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (ASCENDE-RT) study from Canada, a randomized trial comparing the use of dose-escalated external beam radiation therapy (DE-EBRT) and low-dose-rate-brachytherapy (LDR-B) in men with intermediate- and high-risk prostate cancer. The trial included 122 patients with intermediate-risk disease and 276 patients had high-risk disease by NCCN criteria.

gucancerssympaltExclusion criteria included PSA > 40, clinical stage T3b or higher, prior TURP, prostate volume greater than 75cm3, and inability to tolerate anesthesia. Patients received a total of 12 months of androgen deprivation therapy (ADT) with an LHRH antagonist plus a non-steroidal anti-androgen for at least one month as well as whole pelvis EBRT (46Gy) after completion of 8 months of ADT. Patients were then randomized to receive either a conformal 32Gy EBRT boost (DE-EBRT arm) or an iodine-125 LDR boost to a minimum peripheral dose of 115Gy (LDR-B arm). This study found that, over time, LDR-B resulted in a significantly higher relapse-free survival (RFS) with 3-, 5-, 7- and 9-year RFS of 94%, 89%, 86%, and 83% respectively compared to 94%, 77%, 71% and 63% for DE-EBRT (p=0.001). On multivariable analysis controlling for age, percent positive cores, clinical T stage, PSA, risk stratification, number of high-risk features, and Gleason score, receiving LDR-B was associated with a significantly lower likelihood of developing recurrent disease (HR 0.49, 95% CI 0.30-0.80, p=0.004). This difference persisted in both the intermediate- and high-risk groups when analyzed separately. No difference was seen between the LDR-B and DE-EBRT groups with regards to overall survival, prostate cancer-specific survival, or metastasis-free survival. Median overall survival had not been reached at the time of the report of the study, and was estimated to be 13 years on Kaplan-Meier analysis, and thus definitive conclusions regarding the effect of LDR-B on overall survival may be premature at this point. Cumulative 5-year grade 3 urologic toxicity was found to be significantly higher in the LDR-B group compared to the DE-EBRT group (19% vs 5%, p < 0.001). The prevalence of late grade 3 or higher toxicity was noted to be higher in the LDR-B group (8%) compared to the DE-EBRT group (~2%).

In summary, the ASCENDE-RT trial demonstrated a 50% decrease in biochemical relapse with the use of LDR-B in conjunction with ADT and whole pelvis XRT for intermediate- and high-risk prostate cancer when compared to using DE-EBRT with ADT and XRT in patients with intermediate and high-risk prostate cancer. These improved outcomes however come with the cost of higher rates of long-term urologic toxicity.

Presented by Scott Tyldesley, MD, MPA, ABR, FRCPC at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA

University of British Columbia, Vancouver, BC Canada

Reported by Timothy Ito, MD medical writer for UroToday.com

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe